The organization announced a partnership with over 1000 nephrology providers to help implement CMS’ new Kidney Care Choices models beginning this year.
Fresenius Medical Care North America (FMCNA) announced they are partnering with more than 1000 nephrology providers for the new Kidney Care Choices (KCC) models scheduled to begin this year.
The models were announced by CMS in 2019 and a majority of the providers are members of InterWell Health—the largest network of nephrologists in the United States. The partnerships will include 20 of the 55 approved Kidney Contracting Entities announced by CMS.
“We appreciate the more than one thousand nephrology providers who have chosen to partner with us in this important government value-based program to improve care for people living with late-stage kidney disease and kidney failure," said David Pollack, president of the FMCNA Integrated Care Group, in a statement. "Our innovative solutions have shown we can truly make a difference as we work to intervene earlier to treat kidney disease under new value-based models of care."
FMCNA has implemented several value-based care programs with the federal government and private payers since 2005. In the past 7 years, the company has provided support to 500,000 participants in value-based programs and managed risk for over $20 billion in medical expenses. The services and support provided by FMCNA have been expanded to cater to the specific needs of patients with chronic kidney disease (CKD)and end-stage renal disease.
The purpose of FMCNA’s value-based programs is to leverage data to power predictive models that aim to slow progression of kidney disease and reduce hospital admissions. Over 50% of people enrolled in a private payer program have begun home dialysis therapy or had a kidney transplant when transitioning from CKD to kidney failure in the last 5 years. Additionally, patients who planned to start dialysis under these value-based programs represented 2 times the national average.
The company will help manage care for over 50,000 individuals by distributing education and support services to prevent kidney disease progression, increase preemptive transplants, and improve the prevalence of life-sustaining treatments through the Comprehensive Kidney Care Contracting options offered in the KCC.
“Under the direction of the nephrologist, care coordinators will ensure the patient’s plan of care is carried out, providing access to social workers and renal dietitians well before dialysis is needed. Too often patients with kidney disease crash into the hospital with critical health issues and require an urgent start to dialysis, so this program helps incentivize earlier interventions to create a better plan for treatment and management of this disease,” said Terry Ketchersid, MD, MBA, chief medical officer of the FMCNA Integrated Care Group and co-chief medical officer of InterWell Health.
Patients managed under the new models will benefit from FMCNA’s KidneyCare:365 Care Choice Program, which was designed specifically for the CMS initiative. The program was designed to support people living with late-stage CKD using personalized education efforts, hands-on support, and increased care coordination activities to help better manage their disease and related conditions, such as diabetes, hypertension, and behavioral health.
In addition to providing early interventions and prevention opportunities to patients, the program will involve education about kidney disease, related comorbidities, the importance of seeking nephrology care, and dietary and health living information supplied by dietitians and social workers. Education on treatment options for kidney failure, such as kidney transplants and home hemodialysis therapy, will also be provided.
Reference
Fresenius Medical Care North America Partners with 1,000+ Nephrology Providers for New Kidney Care Payment Models [news release]. Waltham, MA: Fresenius Medical Care Holdings; February 9, 2022. fmcna.com/company/our-company/news-releases/fmcna-partners-with-1000-nephrology-providers/. Accessed February 11, 2022.
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen